KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Invested Capital (2016 - 2025)

Eli Lilly (LLY) has disclosed Invested Capital for 17 consecutive years, with $69.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 70.38% year-over-year to $69.0 billion, compared with a TTM value of $69.0 billion through Dec 2025, up 70.38%, and an annual FY2025 reading of $69.0 billion, up 70.38% over the prior year.
  • Invested Capital was $69.0 billion for Q4 2025 at Eli Lilly, up from $23.8 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $69.0 billion in Q4 2025 and bottomed at -$6.3 billion in Q2 2021.
  • Average Invested Capital over 5 years is $17.3 billion, with a median of $16.3 billion recorded in 2021.
  • The sharpest move saw Invested Capital crashed 144.91% in 2021, then soared 72862.39% in 2025.
  • Year by year, Invested Capital stood at $12.4 billion in 2021, then increased by 20.23% to $14.9 billion in 2022, then skyrocketed by 32.15% to $19.7 billion in 2023, then surged by 105.7% to $40.5 billion in 2024, then skyrocketed by 70.38% to $69.0 billion in 2025.
  • Business Quant data shows Invested Capital for LLY at $69.0 billion in Q4 2025, $23.8 billion in Q3 2025, and $34.1 billion in Q2 2025.